CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

Impact · against what's priced in

CG Oncology's stock is likely to react positively to the acceleration of the PIVOT-006 trial timeline, which brings a major value-unlocking catalyst forward by nearly a year. The identification of a large, underserved US market of over 50,000 patients further enhances the potential commercial upside of the Phase 3 data.

CGON+0.60

No priced-in read yet